Evidence map›Paper›PMID 30541779›Full record

ArticlemSphere2018

Protein Microarray Analysis of the Specificity and Cross-Reactivity of Influenza Virus Hemagglutinin-Specific Antibodies.

Rie Nakajima, Medalyn Supnet, Algis Jasinskas, Aarti Jain, Omid Taghavian, Joshua Obiero, Donald K Milton, Wilbur H Chen, Michael Grantham, Richard Webby and 4 more

Open access · goldAbstract read
In one paragraph

Article in mSphere, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 64 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Sterile protection againstLife science alliance · 2024
    Article
  9. Article
  10. Naturally acquired adaptive immunity toClinical & translational immunology · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Rie Nakajima *Vaccine Research and Development Center, Department of Physiology and Biophysics, University of California Irvine, Irvine, California, USA.
Medalyn Supnet *Vaccine Research and Development Center, Department of Physiology and Biophysics, University of California Irvine, Irvine, California, USA.
Algis JasinskasVaccine Research and Development Center, Department of Physiology and Biophysics, University of California Irvine, Irvine, California, USA.
Aarti JainVaccine Research and Development Center, Department of Physiology and Biophysics, University of California Irvine, Irvine, California, USA.
Omid TaghavianVaccine Research and Development Center, Department of Physiology and Biophysics, University of California Irvine, Irvine, California, USA.
Joshua ObieroVaccine Research and Development Center, Department of Physiology and Biophysics, University of California Irvine, Irvine, California, USA.
Donald K MiltonMaryland Institute for Applied Environmental Health, Department of Epidemiology and Biostatistics, University of Maryland, College Park, Maryland, USA.ORCID 0000-0002-0550-7834
Wilbur H ChenCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Michael GranthamMaryland Institute for Applied Environmental Health, Department of Epidemiology and Biostatistics, University of Maryland, College Park, Maryland, USA.
Richard WebbyDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0003-4121-776X
Darrick CarterInfectious Disease Research Institute, Seattle, Washington, USA.
Philip L FelgnerVaccine Research and Development Center, Department of Physiology and Biophysics, University of California Irvine, Irvine, California, USA.
D Huw DaviesVaccine Research and Development Center, Department of Physiology and Biophysics, University of California Irvine, Irvine, California, USA ddavies@uci.edu.
University of California, Irvine · USUniversity of Maryland, College Park · USIcahn School of Medicine at Mount Sinai · USInfectious Disease Research Institute · USSt. Jude Children's Research Hospital · USUniversity of Maryland, Baltimore · US

Funding

TransmissionU19AI089686 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI KAZURA, JAMES WALTER · 2010 to 2016
$9.9M
Predicting naturally acquired humoral immunity against malariaR01AI095916 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI FELGNER, PHILIP LOUIS · 2012 to 2016
$2.1M
NIAID NIH HHS HHSN272201400008CNIAID NIH HHS R01 AI095916NIAID NIH HHS U19 AI089686
6 · The paper itself

Abstract

Current seasonal influenza virus vaccines engender antibody-mediated protection that is hemagglutinin (HA) subtype specific and relatively short-lived. Coverage for other subtypes or even variants within a subtype could be improved from a better understanding of the factors that promote HA-specific antibody cross-reactivity. Current assays to evaluate cross-reactivity, such as the ELISA, require a separate test for each antigen and are neither high-throughput nor sample-sparing. To address this need, we produced an array of 283 purified HA proteins from influenza A virus subtypes H1 to H16 and H18 and influenza B virus. To evaluate performance, arrays were probed with sera from individuals before and after a booster dose of inactivated heterologous H5N1 vaccine and naturally infected cases at presentation and follow-up during the 2010 to 2011 influenza season, when H3N2 was prevalent. The response to the H5 vaccine boost was IgG only and confined to H5 variants. The response to natural H3N2 infection consisted of IgG and IgA and was reactive with all H3 variants displayed, as well as against other group 2 HA subtypes. In both groups, responses to HA1 proteins were subtype specific. In contrast, baseline signals were higher, and responses broader, against full-length HA proteins (HA1+HA2) compared to HA1 alone. We propose that these elevated baseline signals and breadth come from the recognition of conserved epitopes in the stalk domain by cross-reactive antibodies accumulated from previous exposure(s) to seasonal influenza virus. This array is a valuable high-throughput alternative to the ELISA for monitoring specificity and cross-reactivity of HA antibodies and has many applications in vaccine development.

Indexed as

Cross ReactionsAntibodies, ViralHemagglutinin Glycoproteins, Influenza VirusHumansImmunoglobulin AImmunoglobulin GInfluenza A virusInfluenza B virusInfluenza, HumanInfluenza VaccinesProtein Array AnalysisAntibodies, ViralHemagglutinin Glycoproteins, Influenza VirusImmunoglobulin AImmunoglobulin GInfluenza Vaccineshemagglutinininfluenzaprotein microarrays

Identifiers

PMID30541779
PMCPMC6291623
OpenAlexW2903859310

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.